Teva Pharmaceutical Industries (TEVA) Equity Income (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Equity Income for 18 consecutive years, with -$500000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Equity Income rose 50.0% year-over-year to -$500000.0; the trailing twelve-month figure through Jun 2026 stood at $11.5 million (up 666.67% YoY), and the FY2025 full-year result was $15.0 million, up 1400.0% from the prior year.
• Equity Income advanced to -$500000.0 in Q2 2026 per TEVA's latest filing, from -$1.0 million in the prior quarter.
• Across five years, Equity Income topped out at $21.0 million in Q1 2022 and bottomed at -$4.0 million in Q1 2024.
• Historically, Equity Income has averaged $2.2 million across 5 years, with a median of $750000.0 in 2022.
• The sharpest annual moves came in 2022 and 2024: Equity Income soared 600.0% in 2022, then plunged 900.0% in 2024.
• Over 5 years, Equity Income stood at $1.0 million in 2022, then changed by 0.0% to $1.0 million in 2023, then jumped by 200.0% to $3.0 million in 2024, then jumped by 266.67% to $11.0 million in 2025, then slumped by 104.55% to -$500000.0 in 2026.
• According to Business Quant data, Equity Income over the past three periods registered -$500000.0, -$1.0 million, and $11.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.